New ADHD Therapies Make Splash, Meet Payer Skepticism

Editor’s note: A previous version of this article incorrectly stated that Ehave, Inc. is the manufacturer of EndeavorRx. The digital therapeutic device is made by Akili Interactive. This version has been corrected.

In recent months, some innovative treatments have emerged for attention deficit hyperactivity disorder (ADHD), which affects millions of children and is one of the most common neurodevelopmental disorders in childhood. But because those therapies are so new — and in one case, very unconventional — payers appear reticent to change their coverage tactics to accommodate them.

© 2022 MMIT
Leslie Small

Leslie Small

Leslie has been reporting and editing in various journalism roles for nearly a decade. Most recently, she was the senior editor of FierceHealthPayer, an e-newsletter covering the health insurance industry. A graduate of Penn State University, she previously served in editing roles at newspapers in Pennsylvania, Virginia and Colorado.

Related Posts

white-house
May 26

Biden Administration Has Options for Drug Pricing Reform

READ MORE
pharmacist-and-patient
May 26

Court Decision on Accumulator Rule Could Encourage State Bans

READ MORE
doctor-and-infusion-patient
May 26

Third-Party Care Pathways Gain Steam as Cancer Costs Rise

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today